Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda’s Shonan Lab Collaborative Research Initiative Forging Ahead
April 27, 2015
- Janssen Files Risperdal for Irritability Associated with Autistic Disorder in Children
April 27, 2015
- Eisai Launches 2 Anticancer Agents in Mexico
April 27, 2015
- Bayer Seeks Japan Approval of Prostate Cancer Drug Radium-223 Dichloride
April 27, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Astellas Sees 59% Rise in FY2014 Operating Profit
April 24, 2015
- Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US
April 24, 2015
- Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”
April 24, 2015
- Astellas Links Up with US Biotech Potenza on Immuno-Oncology
April 23, 2015
- Shionogi Ups FY2014 Earnings Outlook on ViiV Dividends
April 23, 2015
- Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
- Sales Rep Survey - Part 2: Japanese Drug Makers Forging Specialized Forces in Oncology
April 23, 2015
- Daiichi Sankyo Sells All Shares of Sun Pharma
April 22, 2015
- Merck KGaA, Pfizer Start Multinational PIII Study of Anti-PD-L1 Antibody Avelumab
April 22, 2015
- Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
- Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
- Asahi Kasei Pharma Pulls Plug on Liquid Diet Biz
April 21, 2015
- Takeda, Keio, Niigata Univs in Tripartite Research Pact on RNA-Binding Proteins
April 21, 2015
- AbbVie’s Hepatitis C Drug Gets Priority Review in Japan
April 20, 2015
- Nicholas Grund to Come Back as Genzyme Japan President after 8 Months
April 20, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…